Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

AJMC

Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

By Brigham Walker, PhD
Lalan Wilfong, MD

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

October 5th 2014

ASCO Provides Input on CMMI's

ASCO has been working in parallel with various other institutions to generate a patient-centered oncology payment reform model.

October 5th 2014

In The Literature: NSAID/Statin Influence on PSA in High-Risk Prostate Cancer Patients

The study, published in Cancer Epidemiology, Biomarkers & Prevention, evaluated the influence of NSAIDs and statins on PSA levels in men with a high prostate cancer risk.

October 5th 2014

Ariad's Investigational NSCLC Drug: Breakthrough by FDA

The molecule is being evaluated in crizotinib-resistant ALK-positive NSCLC patients. The results from the phase 1/2 trial with AP26113 were presented at the 2014 European Cancer Congress.

October 4th 2014

JCO Study: MMA Did Not Influence Fee-For-Service Prescribing

The study by Kaiser Permanente found that prescription practices were not much influenced by the decrease in fee-for-service payments for outpatient chemotherapy, due the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

October 4th 2014

Cigna Refers to NCCN Guidelines for Oncology Coverage Decisions

The Cigna-NCCN collaboration will benefit about 12.5 million members.

October 4th 2014

Merck's HPV Vaccine Effective Against 9 Subtypes

The study, conducted in Austria, evaluated the potency of the 9-valent vaccine in preventing the development of cervical precancer in women infected with HPV.

October 3rd 2014

Ambiguous Mammograms: An Emotional and Financial Burden

A study published in a supplement to the Journal of Women's Health looks to the widespread impact of newer screening technologies to improve outcomes.

October 3rd 2014

Value Discussion Reemerges at NICE: Roche's Gazyvaro Rejected

Following Kadcyla, NICE has now rejected another drug from Roche: Gazyvaro for CLL, citing ambiguities in the company's filing and the high cost.

October 3rd 2014

Literature: Germline BRCA Mutations Increase Susceptibility to Salivary Gland Cancer

The study, published online in JAMA Otolaryngology - Head & Neck Surgery, found a significant increase in the rate of head and neck cancers in individuals carrying a BRCA mutation.

October 2nd 2014

New Receptor Target for Glioblastoma Multiforme Holds Promise

A review published in Neuro-Oncology provides insight into some of the molecules being developed to target IL13RÎ±2 in brain tumors.

October 1st 2014

ASCO: Obesity a Risk Factor and Complication in Cancer

ASCO has called for raising awareness to control obesity, as it is not just a risk factor for developing diabetes but also for cancer.

September 30th 2014

ESMO 2014: New Regimen for BRAF-mutated Melanoma

Results from 2 phase 3 trials showed better response rates, progression-free survival, and overall survival when a BRAF inhibitor was combined with a MEK inhibitor, compared with a BRAF inhibitor alone.

Segment 11 - Why It Is an Exciting Time for Immuno-Oncology

September 30th 2014

Segment 11 - Why It Is an Exciting Time for Immuno-Oncology

The panelists offer their closing remarks regarding immuno-oncology's promises and challenges.

Segment 10 - Paying for Combination Therapies

September 30th 2014

Segment 10 - Paying for Combination Therapies

Michael Kolodziej, MD, considers the benefit of combination therapy vs sequential and whether the increased toxicity of combination therapy is worth it.

Segment 9 - Safety Concerns with Oncolytic Virus Therapies

September 30th 2014

Segment 9 - Safety Concerns with Oncolytic Virus Therapies

Although the oncolytic virus therapy being used in the OPTIM trial has been modified in a way that there should be minimal safety concerns, it should still be handled in a way to limit adverse effects and mutations, according to Kimberly Shafer-Weaver, PhD.

Segment 8 - Overall Survival and Ongoing Combination Clinical Trials

September 30th 2014

Segment 8 - Overall Survival and Ongoing Combination Clinical Trials

While it would be nice to think that one and only one therapy would be effective at combatting cancer, combination therapy is needed, Kimberly Shafer-Weaver, PhD, said.

Segment 7 - Ultimate Measures of Efficiency in Immuno-Oncology

September 30th 2014

Segment 7 - Ultimate Measures of Efficiency in Immuno-Oncology

People are now viewing cancer as a kind of chronic disease that can be held at bay, if it cannot be eliminated entirely, according to Kimberly Shafer-Weaver, PhD.

Segment 6 - Including Patient-Reported Outcomes

September 30th 2014

Segment 6 - Including Patient-Reported Outcomes

Although there are some efforts to marry progression-free survival benefits to clinical benefits defined by the patients, the approach is still in the early stages and needs to be moved forward more quickly, according to Michael Kolodziej, MD.

Segment 5 - Establishing the Value of Immunotherapy in Oncology

September 30th 2014

Segment 5 - Establishing the Value of Immunotherapy in Oncology

Michael Kolodziej, MD, explains, the benefit of using biomarkers from a payer perspective to ensure that the right patient gets the right treatment.

Segment 4 - From Animal Models to Human Bodies

September 30th 2014

Segment 4 - From Animal Models to Human Bodies

Although animal models have shown the anti-CTLA-4 antibodies boost the immune system, the human body is not so simple, Jianda Yuan, MD, PhD, said.

Segment 3 - Pairing Patients with the Right Therapies

September 30th 2014

Segment 3 - Pairing Patients with the Right Therapies

In this clip, Kimberly Shafer-Weaver, PhD, discusses specific biomarkers that could establish utilities for specific patient populations and measuring response to drugs.

Segment 2 - Bringing Latest Innovations to the Public

September 30th 2014

Segment 2 - Bringing Latest Innovations to the Public

Jianda Yuan, MD, PhD, explains the importance of bringing the latest innovations to the public and how more data are showing promising immunologic and clinical responses for different types of cancer.

Segment 1 - Immuno-Oncology Education Outreach Efforts

September 30th 2014

Segment 1 - Immuno-Oncology Education Outreach Efforts

Surabhi Dangi-Garimella, PhD, managing editor of The American Journal of Managed Care's Evidence-Based series led the panel of experts in a discussion on immuno-oncology by first talking about checkpoint inhibitors currently in the market and under development.

September 30th 2014

ESMO 2014: Anamorelin Improves Quality of Life in Lung Cancer Patients

Phase 3 trial data from the ROMANA trials, presented at ESMO found that anamorelin improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia.

September 29th 2014

Xalkori to Treat ROS1-Mutated Lung Cancer Patients?

Xalkori, currently approved for treating NSCLC with ALK rearrangements, reduced the tumor size in nearly 75% of the patients and also extended the remission period.

September 29th 2014

Perjeta Improves Survival in HER2-Positive Breast Cancer Patients

The monoclonal antibody extended survival by nearly 16 months compared to those in the control cohort.

September 29th 2014

ESMO 2014: Nivolumab Promise in Melanoma

Results from the CheckMate-037 trial showed a significant increase in duration of response in patients with advanced melanoma administered nivolumab as second- or third-line therapy

September 26th 2014

Hypercalcaemia as an Early Cancer Biomarker

A study published in the British Journal of Cancer discovered a correlation between hypercalcaemia and the risk of cancer, specifically in males.

September 26th 2014

ESMO Congress: Researchers Identify Barriers to Drug Access

The researchers identified discrepancies across the globe in patient access to life-saving cures for cancer.

September 26th 2014

A New Drug Delivery Vehicle: Anthrax Bacteria

Having delivered antibody mimics to cancer cells in vitro, the research group at MIT that conducted the research is now working on evaluating the technique in tumors grown in mice.

...

151 152 153 154 155 156 157 158 159

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions